{"id":42727,"date":"2015-06-30T00:00:00","date_gmt":"2015-06-29T22:00:00","guid":{"rendered":"https:\/\/techma.bakertilly.es\/la-biotecnologia-crece-encuentra-formas-de-financiacion-alternativa-2\/"},"modified":"2025-03-12T11:34:20","modified_gmt":"2025-03-12T10:34:20","slug":"la-biotecnologia-crece-encuentra-formas-de-financiacion-alternativa-2","status":"publish","type":"post","link":"https:\/\/techma.bakertilly.es\/en\/la-biotecnologia-crece-encuentra-formas-de-financiacion-alternativa-2\/","title":{"rendered":"Biotechnology grows and finds alternative forms of financing"},"content":{"rendered":"
According to Asebio, the number of healthcare biotechnology projects developed in Spain grew by 30% in 2015, compared to the same period in 2014. These projects need funding and many of them are turning to alternative financing. Crowdfunding, public aid and venture capital funds are helping to make Spain a biotech country.<\/span><\/address>\n

<\/p>\n

 <\/p>\n

 <\/p>\n

Zeclinics receives funding through crowdfunding<\/span><\/strong><\/span><\/p>\n

The Catalan company ZeClinics<\/span><\/a>,<\/span><\/a><\/span> born at the Pompeu Fabra University in Barcelona,\u00a0<\/strong>haddeveloped a test to personalise cancer treatment with chemotherapy based on xenotransplantation in zebrafish embryos.
\n<\/strong>In order to develop its new product, ZeClinics decided to crowdfund through the crowdfunding platform Capital Cell. 88 days into the campaign, the company has raised \u20ac100,000.<\/span><\/p>\n

\"<\/span>Capital cell is a crowdequity platform that supports entrepreneurs in the health sector in exchange for a stake in the company. The platform, which was created in early 2015, is one of the pioneers focused solely on the healthcare sector. The investment in Zeclinics is the second one made in the platform after Iproteos<\/span><\/strong> to raise another \u20ac100,000,\" says Diego Gutierrez of Abra-Invest.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

New venture capital funds <\/strong><\/span><\/p>\n

In addition to the programme CaixImpulse<\/a>,<\/span> as we discussed in a post last week, the Bot\u00edn Foundation also intends to reform its commitment to the sector.<\/span><\/p>\n

Thanks to CaixImpulse, 15 projects in the field of health will receive the necessary financial support for the preparation and implementation of their value creation and marketing plans for their assets.<\/span><\/p>\n

The Bot\u00edn Foundation is working on the creation of a fund to attract external capital and place it in the biotech sector. The fund, which is expected to be set up before the end of the year, will have a minority shareholding from the Foundation.<\/span><\/p>\n

 <\/p>\n

Biotech companies that have received support from H2020<\/span>
\n<\/strong><\/span><\/p>\n

Companies such as Oxcta<\/a> <\/span>and Proalt <\/span>have recently received funding from Europe through the SME instrument phase II.<\/span>
\nOxcta is a biosecurity company located in the Huesca technology park.<\/span><\/p>\n

Proalt is a biomarker company for various pathologies, especially in cancer.<\/span><\/p>\n

\u00a0If you are looking for public or private financing, we are happy to help you. Contact us on +34.946024142<\/span><\/p>","protected":false},"excerpt":{"rendered":"

According to Asebio, the number of healthcare biotechnology projects developed in Spain grew by 30% in 2015, compared to the same period in 2014. These projects need funding and many of them are turning to alternative financing. Crowdfunding, public aid and venture capital funds are helping to make Spain a biotech country.<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2277],"tags":[238,249],"sectores":[],"tipo-contenido":[2260],"class_list":["post-42727","post","type-post","status-publish","format-standard","hentry","category-multiplos-de-empresas-cotizadas","tag-biotecnologia","tag-inversion-en-biotecnologia","tipo-contenido-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/comments?post=42727"}],"version-history":[{"count":0,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42727\/revisions"}],"wp:attachment":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/media?parent=42727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/categories?post=42727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tags?post=42727"},{"taxonomy":"sectores","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/sectores?post=42727"},{"taxonomy":"tipo-contenido","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tipo-contenido?post=42727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}